There is limited clinical experience with NovoMix 30 in pregnancy.
Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding embryotoxicity or teratogenicity.
In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the 1st trimester and increase subsequently during the 2nd and 3rd trimesters. After delivery, insulin requirements return rapidly to pre-pregnancy levels.
There are no restrictions on treatment with NovoMix 30 during lactation. Insulin treatment of the breastfeeding mother presents no risk to the baby. However, the NovoMix 30 dosage may need to be adjusted.